KEYNOTE-048是一项在37个国家的200家研究中心对未经治疗的局部不可治愈的复发性或转移性HNSCC受试者进行的随机、III期研究[6,7]。受试者按PD-L1表达、p16状态和体能状态分层,并随机分配(1:1:1)至帕博利珠单抗单药、帕博利珠单抗...
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first presentation of interim data from the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as both monotherapy and in comb...
郭晔教授认为,中国诞生引领性研究,就需要像KEYNOTE-048研究一样,采用更大胆的研究设计。 “KEYNOTE-048研究设计最初公布时,业界对该研究能否成功是有很大质疑, 因为它没有采用在标准的抗EGFR+化疗(EXTREME方案)基础上联合免疫治疗, 而是直接让帕博利珠单抗联合化疗挑战EXTREME方案...
Background KEYNOTE-048 (NCT02358031) is a randomized, open-label, phase 3 trial of P or P + chemotherapy (C) vs EXTREME (E) as 1L therapy for R/M HNSCC. At 2nd interim analysis, overall survival (OS) was significantly longer with P than E in patients (pts) with PD-L1 combined ...
港安健康温馨提示:免疫疗法Pembrolizumab联合紫杉醇和卡铂可产生持久的抗肿瘤活性,疗效与该患者群体中的其他一线治疗方案一致,包括KEYNOTE-048[NCT02358031]中的Pembrolizumab联合铂和FU的标准治疗方案。研究结果支持将Pembrolizumab联合紫杉醇和卡铂作为复发性/转移性头颈部鳞状细胞癌患者的额外一线治疗方案,无论患者的PD-L1...
The trial enrolled an estimated 436 patients who were randomized 1:1 to receive either: KEYTRUDA (200 mg) every three weeks (Q3W) for up to 17 cycles (up to approximately one year) plus SBRT once every three days for three, four, five or eight fractions (dependent on tumor type/...
KEYNOTE-048 (NCT02358031) is a randomized, open-label, phase 3 trial of pembrolizumab (pembro) or pembro + chemotherapy (chemo) vs EXTREME (E) as first-line therapy for recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). At the second interim analysis, overa...
Health care professionals may find clinical trial results for KEYNOTE-006 in patients with advanced melanoma.
Background KEYNOTE-048 (NCT02358031) is a randomized, open-label, phase 3 trial of P or P + chemotherapy (C) vs EXTREME (E) as 1L therapy for R/M HNSCC. At 2nd interim analysis, overall survival (OS) was significantly longer with P than E in patients (pts) with PD-L1 combined ...
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-522 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, met its overall su...